GSK has confirmed that Dame Emma Walmsley will step down as its chief executive office (CEO) at the end of this year, with Luke Miels being announced as CEO designate. Miels, who joined GSK in 2017, currently serves as the drugmaker’s chief commercial officer. As incoming CEO, Miels will be responsible for delivering the company’s growth strategy, including an ambition to achieve annual sales of more than £40bn by 2031. “On behalf of the Board, I want to thank Emma and acknowledge her outstanding leadership in delivering a strategic transformation of GSK, including the successful demerger of Haleon. “I am delighted to announce that Luke will be the next CEO of GSK.